stoxline Quote Chart Rank Option Currency Glossary
  
Acurx Pharmaceuticals, Inc. (ACXP)
2.01  -0.12 (-5.63%)    04-19 16:00
Open: 2.08
High: 2.17
Volume: 93,450
  
Pre. Close: 2.13
Low: 1.9701
Market Cap: 29(M)
Technical analysis
2024-04-19 5:07:32 PM
Short term     
Mid term     
Targets 6-month :  2.78 1-year :  3.41
Resists First :  2.38 Second :  2.92
Pivot price 1.92
Supports First :  1.51 Second :  1.26
MAs MA(5) :  1.84 MA(20) :  1.99
MA(100) :  3.15 MA(250) :  2.9
MACD MACD :  -0.2 Signal :  -0.3
%K %D K(14,3) :  48.8 D(3) :  33.2
RSI RSI(14): 45.3
52-week High :  8.81 Low :  1.16
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ACXP ] has closed below upper band by 38.0%. Bollinger Bands are 31% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.17 - 2.18 2.18 - 2.19
Low: 1.95 - 1.96 1.96 - 1.97
Close: 1.99 - 2.01 2.01 - 2.03
Company Description

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Headline News

Mon, 15 Apr 2024
Acurx Pharmaceuticals, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq

Tue, 19 Mar 2024
Healthcare Stocks Moving Tuesday: FUSN, WORX, ELVN, ATNM, EYEN, LTRN, GNPX, ACXP - InvestorsObserver

Tue, 19 Mar 2024
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2023 Earnings Call Transcript - Yahoo Finance

Mon, 18 Mar 2024
Earnings call: Acurx Pharmaceuticals Reports Positive Phase IIb Results - Investing.com

Fri, 26 Jan 2024
New to The Street Announces Episode 551, Five Corporate Interviews, Airing on the FOX Business Network, Monday ... - GlobeNewswire

Mon, 22 Jan 2024
Acurx Stock: Sell-off Presents Opportunity Before Upcoming Data Release - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 16 (M)
Shares Float 13 (M)
Held by Insiders 15.2 (%)
Held by Institutions 11.6 (%)
Shares Short 337 (K)
Shares Short P.Month 292 (K)
Stock Financials
EPS -1.15
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.31
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -106.7 %
Return on Equity (ttm) -243.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -10 (M)
Levered Free Cash Flow -4 (M)
Stock Valuations
PE Ratio -1.75
PEG Ratio 0
Price to Book value 6.28
Price to Sales 0
Price to Cash Flow -3.24
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android